Rubius Therapeutics (NASDAQ:RUBY) and Vigil Neuroscience (NASDAQ:VIGL) Critical Survey
Rubius Therapeutics (NASDAQ:RUBY) and Vigil Neuroscience (NASDAQ:VIGL) Critical Survey
Rubius Therapeutics (NASDAQ:RUBY – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Rubius Therapeutics（纳斯达克股票代码：RUBY — 获取评级）和Vigil Neuroscience（纳斯达克股票代码：VIGL — 获取评级）都是小型医疗公司，但哪家更胜一筹？我们将根据两家企业的盈利能力、分析师建议、股息、风险、收益、估值和机构所有权进行比较。
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and target prices for Rubius Therapeutics and Vigil Neuroscience, as provided by MarketBeat.com.
这是Marketbeat.com提供的Rubius Therapeutics和Vigil Neuroscience最近的评级和目标价格的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rubius Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
| Vigil Neuroscience | 0 | 1 | 4 | 0 | 2.80 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 鲁比乌斯疗法 | 0 | 1 | 0 | 0 | 2.00 |
| 守夜神经科学 | 0 | 1 | 4 | 0 | 2.80 |
Rubius Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 37,995.24%. Vigil Neuroscience has a consensus target price of $18.80, suggesting a potential upside of 88.19%. Given Rubius Therapeutics' higher probable upside, equities research analysts clearly believe Rubius Therapeutics is more favorable than Vigil Neuroscience.
Rubius Therapeutics目前的共识目标价格为8.00美元，这表明潜在的上涨空间为37,995.24％。Vigil Neuroscience的共识目标价为18.80美元，表明潜在的上涨空间为88.19％。鉴于Rubius Therapeutics可能有更高的上涨空间，股票研究分析师显然认为Rubius Therapeutics比Vigil Neuroceut
Risk and Volatility
风险和波动性
Rubius Therapeutics has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.43, meaning that its stock price is 243% more volatile than the S&P 500.
Rubius Therapeutics的beta值为2.38，这意味着其股价的波动性比标准普尔500指数高138％。相比之下，Vigil Neuroscience的beta值为3.43，这意味着其股价的波动性比标准普尔500指数高243％。
Earnings & Valuation
收益与估值
This table compares Rubius Therapeutics and Vigil Neuroscience's revenue, earnings per share and valuation.
该表比较了Rubius Therapeutics和Vigil Neursociale的收入、每股收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rubius Therapeutics | N/A | N/A | -$179.67 million | ($2.38) | -0.01 |
| Vigil Neuroscience | N/A | N/A | -$68.31 million | ($2.19) | -4.56 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 鲁比乌斯疗法 | 不适用 | 不适用 | -1.7967 亿美元 | (2.38 美元) | -0.01 |
| 守夜神经科学 | 不适用 | 不适用 | -6831 万美元 | （2.19 美元） | -4.56 |
Vigil Neuroscience is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
Vigil Neurscience的交易市盈率低于Rubius Therapeutics，这表明它目前是这两只股票中更实惠的一只。
Insider & Institutional Ownership
内部所有权和机构所有权
76.1% of Rubius Therapeutics shares are held by institutional investors. Comparatively, 88.9% of Vigil Neuroscience shares are held by institutional investors. 5.3% of Rubius Therapeutics shares are held by company insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
76.1％的Rubius Therapeutics股票由机构投资者持有。相比之下，88.9％的Vigil Neuroscience股票由机构投资者持有。5.3％的Rubius Therapeutics股票由公司内部人士持有。相比之下，Vigil Neursical 46.6％的股票由公司内部人士持有。强大的机构所有权表明大型基金经理、对冲基金和捐赠机构认为，从长远来看，一家公司的表现将优于市场。
Profitability
盈利能力
This table compares Rubius Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.
该表比较了Rubius Therapeutics和Vigil Neurocescience的净利润率、股本回报率和资产
| Net Margins | Return on Equity | Return on Assets | |
| Rubius Therapeutics | N/A | -212.29% | -86.74% |
| Vigil Neuroscience | N/A | -38.38% | -36.59% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 鲁比乌斯疗法 | 不适用 | -212.29% | -86.74% |
| 守夜神经科学 | 不适用 | -38.38% | -36.59% |
Summary
摘要
Vigil Neuroscience beats Rubius Therapeutics on 9 of the 11 factors compared between the two stocks.
在两只股票比较的11个因素中，Vigil Neuroscience在9个因素上击败了Rubius Ther
About Rubius Therapeutics
关于鲁比乌斯疗法
(Get Rating)
（获取评分）
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.
Rubius Therapeutics, Inc. 从事红细胞治疗药物的开发。它为癌症、自身免疫性疾病、血友病、传染病和代谢性疾病提供药物。该公司成立于2013年4月26日，总部位于马萨诸塞州福克斯伯勒。
About Vigil Neuroscience
关于 Vigil 神经科学
(Get Rating)
（获取评分）
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
Vigil Neuroscionce, Inc. 是一家专注于小胶质细胞的公司，致力于为患有罕见和常见神经退行性疾病的患者、护理人员和家庭开发改善疾病的疗法。其主要候选产品是 VGL101，这是一种全人源单克隆抗体 (mAb)，旨在激活骨髓细胞 2 (TREM2) 上表达的触发受体，该受体处于 I 期，用于治疗成人发作的轴突球体和色素胶质细胞白质脑病，也用于治疗脑肾上腺白质营养不良和阿尔茨海默病。该公司还开发了一种适用于口服给药的小分子 TREM2 激动剂，用于治疗与小胶质细胞功能障碍相关的常见神经退行性疾病。Vigil Neuroscionce, Inc. 成立于 2020 年，总部位于马萨诸塞州剑桥。Vigil Neuroscience, Inc. 作为安进公司的子公司运营。
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Rubius Therapeutics 每日新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Rubius Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。